| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 121 Uppsala |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 66 | 3.6% | 111 | 6.0% | 28 | 1.5% | 2 | 0.1% | 1 | 0.1% | . | . | 1647 | 88.8% | 1855 | 100.0% |
| ASCUS | 48 | 9.9% | 239 | 49.5% | 131 | 27.1% | 1 | 0.2% | 2 | 0.4% | 1 | 0.2% | 61 | 12.6% | 483 | 100.0% |
| LSIL | 27 | 8.4% | 128 | 39.6% | 100 | 31.0% | 1 | 0.3% | 2 | 0.6% | . | . | 65 | 20.1% | 323 | 100.0% |
| ASC-H | 2 | 2.9% | 16 | 23.5% | 44 | 64.7% | 1 | 1.5% | 2 | 2.9% | . | . | 3 | 4.4% | 68 | 100.0% |
| HSIL | . | . | 4 | 7.7% | 38 | 73.1% | 2 | 3.8% | 3 | 5.8% | . | . | 5 | 9.6% | 52 | 100.0% |
| Squamous cell cancer | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
| Totalt | 143 | 5.1% | 498 | 17.9% | 342 | 12.3% | 7 | 0.3% | 11 | 0.4% | 1 | 0.0% | 1781 | 64.0% | 2783 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |